Kentucky Ibogaine Association

A New Path
Through Addiction
& Trauma.

Advocating for safe, regulated access to ibogaine therapy in Kentucky — a clinically promising treatment at the forefront of the psychedelic medicine revolution.

80%
Report elimination or significant reduction of opioid withdrawal symptoms
1,984
Kentuckians lost to overdose in 2023 — ODCP
10+
Countries with legal or unregulated ibogaine treatment clinics
2026
Executive order directs FDA to accelerate ibogaine research

Rooted in Kentucky.
Driven by Science.

The Kentucky Ibogaine Association is a nonprofit advocacy and education organization dedicated to expanding access to ibogaine-assisted therapy for Kentuckians battling addiction, PTSD, and treatment-resistant mental health conditions.

We bridge the gap between emerging psychedelic medicine research and the communities who need it most — working with legislators, clinicians, researchers, and survivors to build a regulatory framework that prioritizes safety, equity, and healing.

Founded 2025
Louisville, Kentucky
501(c)(3)
Pending Nonprofit Status
Iboga Tabernanthe iboga

What Is Ibogaine?

Ibogaine is a naturally occurring psychoactive alkaloid derived from the root bark of the Tabernanthe iboga plant, native to Central Africa. Used for centuries in the Bwiti spiritual tradition of Gabon, it has emerged as one of the most compelling — and clinically studied — candidates in the psychedelic medicine renaissance.

Neurological Reset
Ibogaine acts on multiple receptor systems simultaneously, resetting dopaminergic pathways disrupted by addiction. Clinical studies show a dramatic reduction in withdrawal symptoms and cravings — often within a single session.
Trauma Processing
The extended psychedelic experience (12–36 hours) facilitates deep introspective processing of traumatic memories, often described by participants as addressing the root causes of addictive behavior rather than just the symptoms.
Clinical Evidence
Studies from Johns Hopkins, MAPS, and international researchers demonstrate significant reduction in opioid use disorder, PTSD severity scores, and treatment-resistant depression — with effects lasting months to years after a single treatment.
Safety Considerations
Ibogaine requires cardiac screening and medical supervision. The KIA advocates for regulated clinical settings — not unmonitored use — to ensure every Kentuckian receives this treatment safely under qualified medical care.
N N C CH₃ O Ibogaine — C₂₀H₂₆N₂O ALKALOID STRUCTURE

Four Pillars of Change

Legislative Advocacy
Working directly with Kentucky lawmakers to develop evidence-based regulatory frameworks that allow for safe, supervised ibogaine therapy — modeled after successful legislation in other states.
Safety Standards
Establishing clinical safety protocols, practitioner training standards, and patient screening requirements to ensure every treatment delivered in Kentucky meets the highest medical standards.
Public Education
Cutting through misinformation with evidence-based resources for patients, families, healthcare providers, and policymakers — grounded in peer-reviewed research and lived experience.
Equitable Access
Ensuring ibogaine therapy is not limited to those who can afford overseas treatment. We advocate for insurance coverage, sliding-scale access, and community-based programs that reach underserved Kentuckians.

Kentucky Cannot
Wait for Tomorrow.

Kentucky consistently ranks among the top states for drug overdose mortality. The opioid epidemic has devastated communities across the Commonwealth — from Appalachia to Louisville — leaving families shattered and traditional treatment options falling short.

Conventional addiction treatment has a relapse rate exceeding 70%. We need every tool available. Ibogaine represents a fundamentally different approach — one that has given hope to thousands of Kentuckians forced to travel to Mexico, Canada, or Europe for access.

"The science is clear. The urgency is undeniable. Kentucky deserves access to treatments that work — and ibogaine is among the most promising we have ever seen."

1,984
Kentucky overdose deaths in 2023, per ODCP official report
79%
Of 2023 overdose deaths involved fentanyl — ODCP
~80%
Relapse rate within one year for conventional opioid treatment
$50M
Allocated by Texas in 2025 for FDA-supervised ibogaine clinical trials

Join the Movement

Three ways to help us build a future where every Kentuckian has access to the healing they deserve.

01
Become a Member
Join our growing coalition of patients, clinicians, researchers, and advocates. Membership includes access to our policy updates, research library, and advocacy network.
Join Today
02
Support Our Work
Your donation funds legislative research, community education events, and our scholarship program to help Kentuckians access treatment who cannot currently afford to travel abroad.
Donate Now
03
Share Your Story
If ibogaine has impacted your life or the life of someone you love, your story is our most powerful advocacy tool. We work with you to share it safely and effectively.
Tell Your Story

The Future of Addiction Treatment
Starts in Kentucky.

Stay informed. Get involved. Help us change what's possible.

Contact Us Join the Mailing List